Longeveron LLC
Yahoo Finance • 7 days ago
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
Thepatent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, an amniotic membrane, an umbilical cord... Full story
Yahoo Finance • 27 days ago
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
Issued on behalf of Avaí Bio, Inc. Companies mentioned in this article: Avaí Bio (OTCQB: AVAI), FibroBiologics (NASDAQ: FBLG), Fate Therapeutics (NASDAQ: FATE), Mesoblast (NASDAQ: MESO), Longeveron (NASDAQ: LGVN) Key Takeaways: • Avaí B... Full story
Yahoo Finance • 4 months ago
Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy
Thepatent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to female patients with sexual dysfunction in order to increase sexual quality of lifeFemale sexual dysfun... Full story
Yahoo Finance • 4 months ago
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum
MIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announce... Full story
Yahoo Finance • 4 months ago
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging
Thepatent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging and also to treat patients with non-ischemic dila... Full story
Yahoo Finance • 4 months ago
Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)
Results obtained in the Phase 2 placebo-controlled CLEAR-MIND clinical trial showed that treatment with stem cell therapy laromestrocel was associated with a reduction in MRI measured neuroinflammation compared to placebo across multiple k... Full story
Yahoo Finance • 5 months ago
MODD, LAB, HOWL, COGT, LGVN, ABCL Lead Biotech After-Hours Rally - Nov 26
(RTTNews) - Several biotech and life sciences companies posted notable gains in after-hours trading on Wednesday, November 26, reflecting investor interest despite a relatively quiet news cycle. Modular Medical, Inc. (MODD) shares surged... Full story
Yahoo Finance • 5 months ago
Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)
MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that i... Full story
Yahoo Finance • 5 months ago
Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy
Thepatent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammagingNo approved treatments for aging-related frailty,... Full story
Yahoo Finance • 6 months ago
Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
MIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that... Full story
Yahoo Finance • 6 months ago
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect
Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with HLHSFull enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as... Full story
Yahoo Finance • 6 months ago
Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
MIAMI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that... Full story
Yahoo Finance • 6 months ago
George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors
MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that... Full story
Yahoo Finance • 6 months ago
ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan... Full story
Yahoo Finance • 7 months ago
Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
Exploring potential partnerships and strategic opportunities for the Company’s stem cell therapy program in Alzheimer’s diseaseAlzheimer’s disease development program with positive data in successful Phase 1 and Phase 2a clinical trialsCle... Full story
Yahoo Finance • 7 months ago
Longeveron appoints interim CEO
* Longeveron (NASDAQ:LGVN [https://seekingalpha.com/symbol/LGVN]) appointed Than Powell as interim chief executive officer, effective immediately. * Powell replaces Wa’el Hashad. * Company founder and chief science officer Joshua Har... Full story
Yahoo Finance • 7 months ago
Longeveron® Announces Key Leadership Updates
Than Powell, Chief Business Officer and head of business development, appointed Interim CEODr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of DirectorsWa’el Hashad to step down as CEO and Bo... Full story
Yahoo Finance • 8 months ago
Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference
MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions... Full story
Yahoo Finance • 8 months ago
These stocks have an unusual volume in today's session
These stocks have an unusual volume in today's session [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT ADD [https://www.chartmill.com/stock/quote/ADD/profile] -9.78% The trading volume of COLOR STAR TECHNO... Full story
Yahoo Finance • 8 months ago
Longeveron reports Q2 results
* Longeveron press release [https://seekingalpha.com/pr/20200156-longeveron-announces-second-quarter-2025-financial-results-and-provides-business-update] (NASDAQ:LGVN [https://seekingalpha.com/symbol/LGVN]): Q2 GAAP EPS of -$0.33 beats b... Full story
